Source comparison
CJC-1295 no DAC & Ipamorelin Dosage Comparison
100mcg : 100mcg First-line sleep enhancement protocol 12-18% delta wave power increase 65-70% report subjective improvement within 7-10 nights 30-60 min pre-sleep Optimal starting dose for most individuals. Lowest effective dose with minimal side effect risk.
This comparison does not assign a generated winner or score.
- 100mcg : 100mcg
- First-line sleep enhancement protocol
- 12-18% delta wave power increase
- 65-70% report subjective improvement within 7-10 nights
- 30-60 min pre-sleep
- Optimal starting dose for most individuals. Lowest effective dose with minimal side effect risk. Allows accurate assessment of individual response before titration.
- 150mcg : 150mcg
- Non-responders to 100mcg or moderate sleep disruption
- 18-24% delta wave power increase
- 80-85% cumulative response (including prior non-responders)
- Appropriate second-step titration for confirmed non-responders at lower dose. Increases GH pulse amplitude without significantly raising cortisol spillover risk in most users.
- 200mcg : 200mcg
- Severe sleep fragmentation or confirmed low endogenous GH
- 22-28% delta wave power increase
- 85-90% cumulative response; 10-15% experience rebound wakefulness
- Upper therapeutic ceiling. Further increases don't proportionally improve sleep and may cause early-morning wakefulness as GH levels drop. Reserve for documented non-response to 150mcg after 14+ nights.
- >200mcg : >200mcg
- Not recommended for sleep applications
- Variable; often decreases total SWS due to fragmentation
- High rate of adverse sleep outcomes (middle-of-the-night waking)
- N/A
- Exceeds receptor saturation threshold for pulsatile GH benefit. Increased cortisol elevation risk disrupts slow-wave sleep architecture despite higher total GH output. Avoid unless under direct clinical supervision for non-sleep indications.